Post by Alvotech

Today we announced the resubmission of our U.S. Biologics License Applications for two proposed biosimilar candidates in immunology and ophthalmology. These submissions reflect the strength of our fully integrated development and manufacturing platform and the dedication of teams across our global organisation. We remain committed to expanding access to biologic medicines and improving the availability of biologic treatments for patients worldwide. Read more in the press release (link in the comments) #Biosimilars #Biologics #HealthcareInnovation #AccessToMedicines #Betteraccessbetterlives